Muscle dysfunction in axial spondylarthritis: the MyoSpA study

Neto, Ana Serrão; Torres, Rita; Ramiro, Sofía; Sardoo, Atlas; Rodrigues-Manica, Santiago; Lagoas-Gomes, João; Domingues, Lúcia; Crespo, Carolina Lage; Teixeira, Diana; Sepriano, Alexandre; Masi, Alfonse T.; Nair, Kalyani; Gomes‐Alves, Patrícia; Borges‐Costa, João; Branco, Jaime; Pimentel-Santos, Fernando

doi:10.55563/clinexprheumatol/9ljng7

Cited by 6 publications

(2 citation statements)

References 14 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously shown, patients with axSpA are generally less physically active, have often more muscle weakness and sarcopenia as compared to healthy controls, but these effects are more pronounced in older patients with longstanding disease. 24 , 46 – 50 There is some evidence that gait is altered in patients with axSpA leading to reduced speed, cadence, stride length, and swing time. 51 , 52 …”

Section: Discussionmentioning

confidence: 99%

Impact of daily physical therapy over 2 weeks on spinal mobility including objective electronic measurements and function in patients with axial spondyloarthritis

Kiefer,

Schneider,

Braun

et al. 2024

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Background: Patients with axial spondyloarthritis (axSpA) are often compromised by impaired function and mobility. The standardized 2-week inpatient program ‘multimodal rheumatologic complex treatment’ (MRCT) was designed for patients with axSpA. The Epionics SPINE (ES) is an objective tool validated to assess mobility. Objective: To investigate the impact of MRCT on physical function and mobility including range of motion (RoM) and kinematics (RoK). Design: Single-center interventional, observational trial. Methods: Patients with axSpA presenting with high disease activity and impaired physical function were consecutively recruited to undergo MRCT. Assessments performed before (V1) and after (V2) the intervention included Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis functional index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), the ankylosing spondylitis physical performance index (ASPI), the Short Physical Performance Battery (SPPB), and ES measurements. Results: At baseline, the 80 patients included had: BASDAI 5.5 ± 1.5, BASFI 5.6 ± 2.0, BASMI 4.2 ± 1.8, SPPB 13.8 ± 1.8, and ASPI 37.3 ± 18.1 s. Clinically relevant improvements between V1 versus V2 were noted for BASFI, BASMI, and all other assessments ( p < 0.001), and also for ES measures of RoK (all p < 0.003) and RoM (all p < 0.04), while a positive trend was seen for flexion and extension (RoM). There was no significant effect of changes in medication (all p > 0.05). Conclusion: The 2-weeks MRCT was associated with definite improvements of function and mobility. Importantly, the effect of this extensive physical activity was confirmed by using the ES as an objective tool to assess spinal mobility. The ES demonstrated for the first time that the RoK of spinal mobility can significantly improve related to an exercise intervention. Trial registration: Ethical Committee: Ruhr-Universität (reference-number: 19-6735-BR).

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of daily physical therapy over 2 weeks on spinal mobility including objective electronic measurements and function in patients with axial spondyloarthritis

Kiefer,

Schneider,

Braun

et al. 2024

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…Presarcopenia, sarcopenia, and cachexia were associated with higher BASDAI levels and lower bone mineral density. Neto et al 42 investigated muscle physical properties, strength, mass, physical performance, and the prevalence of sarcopenia by EWGSOP2 criteria in 27 patients with axial SpA compared with 27 healthy controls. No participants were defined as having sarcopenia.…”

Section: Systemic Lupus Erythematosusmentioning

confidence: 99%

Sarcopenia in Immune-Mediated Rheumatic Diseases—Review

et al. 2022

View full text Add to dashboard Cite

Introduction Sarcopenia is a condition characterized by decreased muscle strength and muscle mass, which can impact physical function. Sarcopenia develops as a consequence of age-related decline (primary sarcopenia) and has a major impact on physical, social, and emotional well-being. In addition, patients with rheumatic diseases may suffer from sarcopenia independently of aging (secondary sarcopenia). Exercise, pharmacological treatments, and nutritional supplementation are some of the strategies used for the management of sarcopenia in the general population. The aim of this review is to summarize the evidence around the prevalence and impact of sarcopenia in patients with rheumatic diseases. Conclusions From our review, we can state that sarcopenia is a common and prevalent condition among the rheumatic diseases. Furthermore, the impacts of sarcopenia are not well-appreciated, and the implementation of treatment strategies has not been widespread. Strategies such as exercise and some pharmacological treatments are effective in improving physical and functional impairment related to these conditions. Future Research Directions in the Field New pharmacological treatments are being actively studied and may contribute in the future to the management of sarcopenia.

show abstract

Systemerkankungen des Bewegungsapparates

Joisten

2023

Repetitorium Sportmedizin

View full text Add to dashboard Cite

Muscle dysfunction in axial spondylarthritis: the MyoSpA study

Cited by 6 publications

References 14 publications

Impact of daily physical therapy over 2 weeks on spinal mobility including objective electronic measurements and function in patients with axial spondyloarthritis

Impact of daily physical therapy over 2 weeks on spinal mobility including objective electronic measurements and function in patients with axial spondyloarthritis

Sarcopenia in Immune-Mediated Rheumatic Diseases—Review

Systemerkankungen des Bewegungsapparates

Contact Info

Product

Resources

About